人细胞融合肝癌疫苗的制备及其融合细胞百分率的检测  

HUMAN TUMOR VACCINE GENERATED BY FUSION OF HEPATOCELLULAR CARCINOMA CELLS WITH ACTIVATED B CELLS AND ITS FUSION RATE DETECTION

作　　者：张从昕[1] 季军捷[1] 钱卫珠[1] 范晓强[1] 范瑞芳[1] 卫立辛[1] 吴孟超[1] 郭亚军[1] 

机构地区：[1]第二军医大学东方肝胆外科医院,上海200438

出　　处：《解放军医学杂志》2002年第9期808-809,共2页Medical Journal of Chinese People's Liberation Army

基　　金：国家自然科学基金资助课题 (编号 397890 1 0 )

摘　　要：手术取病人新鲜肝癌组织及部分脾脏 ,分离纯化、激活B细胞 ,应用PEG融合肝癌细胞与激活B细胞 ,经培养灭活制得肿瘤疫苗。同时测定了融合肝癌疫苗的融合率、冻存后复苏活细胞百分率。结果显示 ,3例融合细胞的融合率分别为 6 6 84 %、74 4 3%、76 5 5 % ,融合细胞经DMSO和甘油冻存后复苏活细胞百分率分别为 95 %、97%。研究表明 ,人细胞融合肝癌疫苗具有很高的融合率和冻存后复苏活细胞百分率 ,便于制备及储存 ,适合临床应用。Fresh hepatocarcinoma tissue and spleen samples were taken from patients during surgery. B cells from spleen were purified and activated. The hepatocarcinoma vaccine was made by cell fusion between hepatic tumor cells and activated B cells. PEG was used as the fusion agent. The fusion cells were cultured and deactivated. MHC Ⅱ and B7 molecules on activated B cells were determined by flow cytometry. Fusion rate and recovery rate of cells after refrigeration were determined respectively at the same time. The results showed that MHC Ⅱ and B7 molecules on the activated B cells were enhanced comparing with B cell. The fusion rates of three cases were 66 84%, 74 43%, and 76 55%, respectively. The recovery rates of cells were 95% and 97% after DMSO and glycerol refrigeration, respectively. The results suggest that the hepatocarcinoma vaccine owns high fusion rate and recovery rate of cells after refrigeration. It's easy to make and store. So the hepatocarcinoma vaccine is suitable for clinical use.

关 键 词：人细胞融合肝癌疫苗 制备 融合细胞百分率 检测 

分 类 号：R735.703[医药卫生—肿瘤]